News

Under the partnership, the companies will jointly select two preclinical drug candidates, one in inflammation and the other in oncology. Two preclinical drug candidates will be targeted, one

Known as the Program in Innovative Therapeutics for Connecticut’s Health or PITCH, the initiative aims to translate basic science discoveries into therapeutic strategies that can be used to

Accessible through Lexicomp Online and Lexicomp® Mobile App offerings, Lexi-Drugs will now be used by CMS and healthcare professionals as a trusted knowledge resource to help determine coverage

The product is currently in Phase 2a clinical trial to treat hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant MRSA strains. Aridis

Situated in Boulder, Colorado, the LakeCentre plant will increase manufacturing and production capacity to support AstraZeneca’s portfolio of biologics medicines. AstraZeneca aims to undertake refurbishment and infrastructure improvements

Patient dosing and follow-up is underway and the company expects to reveal top-line results later this year. SMT19969 is a novel, oral antibiotic designed to selectively target C.

SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on cancer stem cells (CSCs) and tumor bulk of BPDCN, AML, and other hematologic cancers. It

The facility, dubbed JLABS @ Toronto, is due to open in spring 2016. It will serve as a home for about 50 startups focused on biotechnology and pharmaceuticals,

The update enables the company to use Daklinza in combination with sofosbuvir for 12 weeks in patients without cirrhosis in all 28 Member States of the European Union.